0.79

0.37% -0.0029

Matinas Biopharma Holdings Inc (MTNB)

Overview News Price History Discussions Forecast

Matinas Biopharma Holdings Inc stock is traded at $0.79, with a volume of 19,355. It is down -0.37% in the last 24 hours and down -37.80% over the past month. Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.

Previous Close:

$0.7929

Open:

$0.8899

24h Volume:

19,355

Relative Volume:

0.52

Market Cap:

$5.06M

Revenue:

Net Income/Loss:

$-21.13M

P/E Ratio:

-0.1649

EPS:

-4.79

Net Cash Flow:

$-16.95M

1W Performance:

+0.00%

1M Performance:

-37.80%

6M Performance:

-10.23%

1Y Performance:

+35.97%

1-Day Range:

$0.7655

$0.8899

1-Week Range:

$0.7561

$0.975

52-Week Range:

$0.4748

$3.09

Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile

Name

Matinas Biopharma Holdings Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

908-443-1860

Address

1545 Route 206 South, Suite 302, Bedminster, NJ

Employee

Twitter

@MatinasBio

Next Earnings Date

2024-11-06

Latest SEC Filings

MTNB's Discussions on Twitter

Compare MTNB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MTNB Matinas Biopharma Holdings Inc	0.79	5.08M	0	-21.13M	-16.95M	-4.79
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Aug-26-20	Resumed	Piper Sandler	Overweight
Jan-27-20	Initiated	Piper Sandler	Overweight
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Jan-09-20	Initiated	Aegis Capital	Buy
Jun-26-19	Initiated	H.C. Wainwright	Buy

View All

Matinas Biopharma Holdings Inc Stock (MTNB) Latest News

Dec 13, 2025

Matinas BioPharma amends CEO employment agreement to revise retention bonus terms - Investing.com Canada

Dec 13, 2025

Dec 12, 2025

Matinas BioPharma Amends CEO Employment Agreement - TipRanks

Dec 12, 2025

Matinas BioPharma amends CEO employment agreement to revise retention bonus terms By Investing.com - Investing.com South Africa

Dec 12, 2025

Dec 07, 2025

Matinas BioPharma CFO Resignation Announced - MSN

Dec 07, 2025

Dec 05, 2025

Forecast Cut: Will Matinas BioPharma Holdings Inc stock gain from strong economyMarket Rally & AI Enhanced Market Trend Forecasts - BỘ NỘI VỤ

Dec 05, 2025

How Matinas Biopharma Holdings Inc. stock reacts to stronger dollarJuly 2025 Sentiment & Free Risk Controlled Daily Trade Plans - Newser

Dec 05, 2025

What insider trading reveals about Matinas BioPharma Holdings Inc. stockQuarterly Market Review & Accurate Buy Signal Notifications - Newser

Dec 05, 2025

Dec 04, 2025

Why Matinas Biopharma Holdings Inc. stock attracts wealthy investorsPortfolio Gains Report & Proven Capital Preservation Methods - Newser

Dec 04, 2025

Will Matinas BioPharma Holdings Inc. stock gain from strong economyEarnings Beat & Free Low Drawdown Momentum Trade Ideas - Newser

Dec 04, 2025

Will Matinas Biopharma Holdings Inc. stock sustain uptrend momentum2025 Year in Review & Fast Entry and Exit Trade Plans - Newser

Dec 04, 2025

How Matinas BioPharma Holdings Inc. (6LJ0) stock reacts to new regulationsTake Profit & Intraday High Probability Setup Alerts - Newser

Dec 04, 2025

Dec 03, 2025

Is Matinas Biopharma Holdings Inc. stock a top hedge fund pickOil Prices & High Return Trade Opportunity Guides - Newser

Dec 03, 2025

Why Matinas Biopharma Holdings Inc. stock benefits from AI revolutionQuarterly Profit Review & Risk Adjusted Buy and Sell Alerts - Newser

Dec 03, 2025

Nov 29, 2025

MTNB (Matinas BioPharma Holdings) Current Ratio : 3.78 (As of Sep. 2025) - GuruFocus

Nov 29, 2025

Nov 27, 2025